This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Donor hearts can be reprogrammed with medication for longer storage, improved transplant outcomes

Donor hearts can be reprogrammed with medication for longer storage, improved transplant outcomes
A graphic depicting the set up for the ex-vivo pig heart infusion apparatus. Credit: Lei, et al., Science Translational Medicine (2023)

Hundreds of thousands of Americans with heart failure are sick enough to benefit from a transplant, yet only around 4,000 heart transplants are performed annually.

One reason for this gap is the during which a can survive outside the donor body before transplant hovers around four hours. And the longer it takes for the donor heart to be transported to the recipient, the more likely that heart will not work well once it's implanted.

Using a drug previously used to treat seizures, researchers have found a way to reprogram to boost the production of a beneficial enzyme that both increases the amount of time they can be stored and transported, as well as improves their function after they are transplanted, a study published in Science Translational Medicine suggests.

"This technology that coaxes donor hearts to mount adaptive responses to existence outside the body could lead to a not only for extending the time a heart can be outside of the donor during transport but for improving heart function after transplant," said Paul C. Tang, M.D., Ph.D., senior author of the study and a surgeon at University of Michigan Health. "Being able to extend the storage of hearts by figuring out the pathways that define and modulate preservation biology is the first step toward the ultimate goal of organ banking."

In around 10-20% of , transplanted hearts cannot pump sufficient blood to supply to the rest of the body. The condition, known as primary graft dysfunction, is responsible for nearly 40% of early deaths after heart transplant and can still predictably occur despite newer machine heart perfusion technology.

Investigators in the study sought to reduce primary graft dysfunction by increasing the production of itaconate, an anti-inflammatory and antioxidant metabolite produced by the enzyme Irg1. Itaconate neutralizes the effects of succinate, a harmful molecule which accumulates while a heart is on ice and creates a flash of oxidative stress following blood reperfusion that causes the heart to malfunction.

"Current donor preservation techniques focus on cold storage and, more recently, technologies that keep the organs perfused during transport to minimize injury to the heart, but there are no targeted molecular therapies to improve heart preservation in a very precise fashion," said Ienglam Lei, Ph.D., first author of the study and a research investigator in the Department of Cardiac Surgery at U-M Medical School.

When an organ is in cold storage, succinate is free to build up in excess—more ammunition for stress against the soon-to-be-transplanted heart. To reprogram hearts to take on the heart-damaging succinate, researchers used , a histone deacetylase inhibitor previously used as an anti-seizure medication. They found that it defused a significant amount of this cumulative stress in both human and pig hearts by instructing the donor heart to produce antioxidants and anti-inflammatory proteins while preserved on ice.

"Using a metabolomic screen, we found that valproic acid can reprogram the donor heart to produce beneficial itaconate during preservation," said Tang, who is also an assistant professor of cardiac surgery at U-M Medical School. "We showed previously that hearts are in fact biologically very active while stored on ice, which opens up the therapeutic opportunity to help it protect itself from metabolic stress during this time. Not only could this possibly double the time a heart could spend in , but it could reduce the risk of primary graft dysfunction to make transplant even safer."

Valproic acid is approved by the FDA to treat seizures, bipolar disorder and for the prevention of migraine headaches. For that reason, researchers believe the road to a clinical trial may be shorter.

"This discovery will buy time to allow a to reach patients in parts of the country not previously accessible—greatly impacting the landscape of organ in America," said Y. Eugene Chen, M.D., Ph.D., co-author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at U-M Medical School. "The overarching principles here can be expected to apply to preservation of other organs, such as lungs, livers and kidneys. I would also anticipate this treatment strategy to be relevant for other conditions where is disrupted, such as or stroke."

Additional authors include, Wei Huang, M.D.., Ph.D., Suyash Naik, B.S., Miriyam Ghali, B.S., Liu Liu, Ph.D., Pracis D. Pagani, M.D., Ph.D., Ashraf Abou el ela, M.D., Bertram Pitt, M.D., Jeffrey L. Platt, M.D., Marilia Cascalho, M.D., Ph.D., Zhong Wang, Ph.D., Richard M. Mortensen, M.D., Ph.D., all of University of Michigan, Pierre Emmanuel Noly, M.D., Ph.D., Université de Montréal, and Jordan S. Pober, M.D., Ph.D., Yale University.

More information: Ienglam Lei et al, Metabolic reprogramming by immune-responsive gene 1 upregulation improves donor heart preservation and function, Science Translational Medicine (2023). DOI: 10.1126/scitranslmed.ade3782.

Journal information: Science Translational Medicine
Citation: Donor hearts can be reprogrammed with medication for longer storage, improved transplant outcomes (2023, February 8) retrieved 15 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Innovative 'heart in a box' technology gives hope to transplant patients


Feedback to editors